CFDE Data Portal | Search AGAP11

	Label	Description
	AGAP11 associations Collection (Entity type)	Associations for AGAP11_associations
	AGAP11 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	AGAP11 Gene (Entity type)	ENSG00000151303 - ArfGAP with GTPase domain, ankyrin repeat and PH domain 11
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE104526 p53 LSD1 inhibition 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE161073 IDH1 inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

AGAP11 associations

Associations for AGAP11_associations

AGAP11 associations.tsv

A file from IDG as part of the Harmonizome project

AGAP11

ENSG00000151303 - ArfGAP with GTPase domain, ankyrin repeat and PH domain 11

GSE189035 inositol 2 v 4 human dn

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human up

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 7 human dn

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE104526 p53 LSD1 inhibition 1 v 0 human dn

A Gene Set from LINCS

GSE161073 IDH1 inhibition 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.